Active substances
Dydrogesterone + Estradiol
- SFDA 2
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FEMOSTON 1-5 TABLET | 1,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 32.75 | NCE · Prescription | ABBOTT BIOLOGICALS | Valid |
| FEMOSTON 2-10 TABLET | 2,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 29.50 | NCE · Prescription | ABBOTT BIOLOGICALS | Valid |
Indications — CHI Daman Drug Formulary
ENDOMETRIOSIS; HYPERPROLACTINEMIA; MENOPAUSE; OSTEOPOROSIS
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Estradiol 1mg / Dydrogesterone 5mg tablets | £24.43 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Estradiol 500micrograms / Dydrogesterone 2.5mg tablets | £24.43 | 84 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.